Cannara Biotech Inc
Cannara Biotech Inc., together with its subsidiaries, engages in the indoor cultivation, processing, and sale of cannabis and cannabis-derivative products in Canada. The company operates in two segment Cannabis operations and Real estate operations. It offers its products under TRIBAL, nugz, and ORCHID CBD brand name. The company sells its products through wholesalers and online merchandisers. I… Read more
Cannara Biotech Inc (LOVFF) - Total Liabilities
Latest total liabilities as of November 2025: $62.63 Million USD
Based on the latest financial reports, Cannara Biotech Inc (LOVFF) has total liabilities worth $62.63 Million USD as of November 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Cannara Biotech Inc - Total Liabilities Trend (2018–2025)
This chart illustrates how Cannara Biotech Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Cannara Biotech Inc Competitors by Total Liabilities
The table below lists competitors of Cannara Biotech Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sunmow Holding Bhd
KLSE:03050
|
Malaysia | RM91.54 Million |
|
Lalin Property Public Company Limited
BK:LALIN
|
Thailand | ฿8.19 Billion |
|
Hilbert Group AB Series B
ST:HILB-B
|
Sweden | Skr89.02 Million |
|
Suominen Oyj
HE:SUY1V
|
Finland | €177.19 Million |
|
Incross Co. Ltd
KQ:216050
|
Korea | ₩123.08 Billion |
|
Sumeeko Industries Co Ltd
TWO:2066
|
Taiwan | NT$1.63 Billion |
Liability Composition Analysis (2018–2025)
This chart breaks down Cannara Biotech Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.70 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.56 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.36 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cannara Biotech Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cannara Biotech Inc (2018–2025)
The table below shows the annual total liabilities of Cannara Biotech Inc from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-08-31 | $66.43 Million | -0.51% |
| 2024-08-31 | $66.77 Million | +8.08% |
| 2023-08-31 | $61.78 Million | +4.92% |
| 2022-08-31 | $58.88 Million | +110.99% |
| 2021-08-31 | $27.91 Million | +69.28% |
| 2020-08-31 | $16.49 Million | -9.29% |
| 2019-08-31 | $18.17 Million | +28.73% |
| 2018-08-31 | $14.12 Million | -- |